Shogo Kobayashi

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 214 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +9

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hiroki Murai, Takahiro Kodama, Kazuki Maesaka et al. · Hepatology · 2022 · 163 citations · Full text

The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease

Junji Tanaka, Masahiro Imamura, M Kasai et al. · Bone Marrow Transplantation · 1997 · 75 citations

Inflammation, Type 1, Cell Therapy +12

Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodyspplastic syndromes

Masahiro Imamura, Shogo Kobayashi, Kazuhiro Sakurada et al. · Annals of Hematology · 1994 · 35 citations

Hematological Malignancy, Bone Marrow Failure, Autoimmune Disease +10

Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy

Kazuhiro Mochizuki, Satoshi Kawana, Shoki Yamada et al. · Pediatric Hematology and Oncology · 2019 · 34 citations · Full text

Immunology, Immunoediting, Novel Immunotherapy +20